External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries.
The hypertensive disorders of pregnancy are leading causes of maternal mortality and morbidity, especially in low- and middle-income countries. Early identification of women with preeclampsia and other hypertensive disorders of pregnancy at high risk of complications will aid in reducing this health burden. The fullPIERS model (Preeclampsia Integrated Estimate of Risk) was developed for predicting adverse maternal outcomes from preeclampsia using data from tertiary centers in high-income countries and uses maternal demographics, signs, symptoms, and laboratory tests as predictors. We aimed to assess the validity of the fullPIERS model in women with the hypertensive disorders of pregnancy in low-resourced hospital settings. Using miniPIERS data collected on women admitted with hypertensive disorders of pregnancy between July 2008 and March 2012 in 7 hospitals in 5 low- and middle-income countries, the predicted probability of developing an adverse maternal outcome was calculated for each woman using the fullPIERS equation. Missing predictor values were imputed using multivariate imputation by chained equations. The performance of the model was evaluated for discrimination, calibration, and stratification capacity.Among 757 women with complete predictor data (complete-case analyses), the fullPIERS model had a good area under the receiver-operating characteristic curve of 0.77 (95% confidence interval, 0.72-0.82) with poor calibration (P<0·001 for the Hosmer-Lemeshow goodness-of-fit test). Performance as a rule-in tool was moderate (likelihood ratio: 5.9; 95% confidence interval, 4.23-8.35) for women with ≥30% predicted probability of an adverse outcome. The fullPIERS model may be used in low-resourced setting hospitals to identify women with hypertensive disorders of pregnancy at high risk of adverse maternal outcomes in need of immediate interventions.
From the Department of Obstetrics and Gynaecology (U.V.U., T.L.) and Department of Anaesthesiology (B.P.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research, Vancouver, Canada (U.V.U., B.P., T.L.); Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (L.A.M., P.v.D.); and Department of Obstetrics and Gynaecology, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom (L.A.M., P.v.D.). vivian.ukah@cw.bc.ca.
U Vivian
UV
Ukah
From the Department of Obstetrics and Gynaecology (U.V.U., T.L.) and Department of Anaesthesiology (B.P.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research, Vancouver, Canada (U.V.U., B.P., T.L.); Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (L.A.M., P.v.D.); and Department of Obstetrics and Gynaecology, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom (L.A.M., P.v.D.).
Beth
B
Payne
From the Department of Obstetrics and Gynaecology (U.V.U., T.L.) and Department of Anaesthesiology (B.P.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research, Vancouver, Canada (U.V.U., B.P., T.L.); Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (L.A.M., P.v.D.); and Department of Obstetrics and Gynaecology, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom (L.A.M., P.v.D.).
Tang
T
Lee
From the Department of Obstetrics and Gynaecology (U.V.U., T.L.) and Department of Anaesthesiology (B.P.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research, Vancouver, Canada (U.V.U., B.P., T.L.); Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (L.A.M., P.v.D.); and Department of Obstetrics and Gynaecology, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom (L.A.M., P.v.D.).
Laura A
LA
Magee
From the Department of Obstetrics and Gynaecology (U.V.U., T.L.) and Department of Anaesthesiology (B.P.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research, Vancouver, Canada (U.V.U., B.P., T.L.); Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (L.A.M., P.v.D.); and Department of Obstetrics and Gynaecology, St George's University Hospitals, NHS Foundation Trust, London, United Kingdom (L.A.M., P.v.D.).
Peter
P
von Dadelszen
D000328:Adult; D001938:Brazil / Q000453:epidemiology; D005260:Female; D005367:Fiji / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000453:epidemiology*; D007182:Income; D009017:Morbidity / Q000639:trends; D010154:Pakistan / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D013019:South Africa / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D014454:Uganda / Q000453:epidemiology; D055815:Young Adult
hypertension; mortality; preeclampsia; pregnancy; prognosis